729 results on '"Kallenberg, Cees G. M."'
Search Results
2. Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: the role for autoantibody guided and anti-bacterial treatment
3. Standard therapeutic regimens for vasculitis
4. Systemic vasculitides, an introduction
5. Experimental Therapies in Sjögren’s Syndrome
6. ANCA-Associated Vasculitis
7. POSITION PAPER: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
8. Pulmonary Manifestations of Systemic Vasculitides
9. ANCA: their clinical relevance
10. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
11. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
12. Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Autoimmune Liver Disease
13. Antineutrophil Antibodies in Inlammatory Bowel Disease Recognize Different Antigens
14. Anti-Neutrophil Cytoplasmic Antibodies in Giant Cell Arteritis and Polymyalgia Rheumatica
15. Induction of an Humoral and Cellular (Auto) Immune Response to Human and Rat Myeloperoxidase(MPO) in Brown-Norway(BN), Lewis and Wistar Kyoto(WKY) Rat Strains
16. Perinuclear Antineutrophil Cytoplasmic Antibodies (P-ANCA): Clinical Significance and Relation to Antibodies Against Myeloid Lysosomal Enzymes
17. Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3.
18. Anti-Neutrophil Cytoplasmic Antibodies (ANCA): New Tools in the Diagnosis and Follow-Up of Necrotizing Glomerulonephritis and Vasculitis
19. Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro
20. High mobility group box 1 serum levels are increased in Behçet’s disease, but not associated with disease activity or disease manifestations
21. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?
22. Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
23. Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism.
24. Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis
25. Treatment of ANCA-Associated Vasculitis, Where to Go?
26. The impact factor of rheumatology journals: an analysis of 2008 and the recent 10 years
27. Pathogenesis of ANCA-Associated Vasculitis, an Update
28. Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
29. Pathophysiology of ANCA-Associated Small Vessel Vasculitis
30. Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission
31. Key advances in the clinical approach to ANCA-associated vasculitis
32. No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis
33. Complement Activation Is Involved in Renal Damage in Human Antineutrophil Cytoplasmic Autoantibody Associated Pauci-Immune Vasculitis
34. The Last Classification of Vasculitis
35. Plasma kynurenine and related measures in tic disorder patients
36. Plasma Factors in Severe Early-Onset Preeclampsia Do Not Substantially Alter Endothelial Gene Expression In Vitro
37. Diversity of PR3-ANCA Epitope Specificity in Wegener's Granulomatosis. Analysis Using the Biosensor Technology
38. Autoantibodies and Vascular Inflammation
39. RENAL VASCULITIS IN 2012: Reclassification and the introduction of biologicals
40. Experimental Therapies in Sjögren’s Syndrome
41. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögrenʼs syndrome: data from a placebo-controlled clinical trial
42. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögrenʼs syndrome after B cell depletion therapy
43. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
44. VASCULITIS SYNDROMES: Peripheral neuropathy in AAV—when vasculitis hits a nerve
45. Circulating Markers of Vascular Injury and Angiogenesis in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
46. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission
47. FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells
48. Granulomatosis with Polyangiitis (Wegenerʼs): An alternative name for Wegenerʼs Granulomatosis
49. Granulomatosis with polyangiitis (Wegenerʼs): An alternative name for Wegenerʼs granulomatosis
50. Pathogenesis of ANCA-associated vasculitides
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.